

04-25-02 111

0300  
PATENT #7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 99-274-F)

In the Application of:

Karl Tryggvason, et al.

Serial No. 10/037,182

Filed: December 21, 2001

For: Isolated Laminin 10

Examiner: To be assigned

Art Unit: To be assigned

Commissioner for Patents  
Washington, D.C. 20231


Sir:

**TRANSMITTAL LETTER**

In regard to the above-identified application we are transmitting herewith the attached:

1.
  - a. Information Disclosure Statement;
  - b. Form 1449 and ninety-six (95) cited references; and
  - c. Postcard.
2. With respect to additional fees:
  - a. No additional fee is required
3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 CFR § 1.10: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 24<sup>th</sup> day of April, 2002. Express Mail Label: **EL604657902US**

By:

  
David Harper

Reg. No. 42,636

McDonnell, Boehnen Hulbert & Berghoff  
300 South Wacker Drive  
Chicago, IL 60606



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 99-274-F)

In the Application of: )  
Karl Tryggvason, et al. )  
Serial No. 10/037,182 ) Examiner: To be assigned  
Filed: December 21, 2001 ) Art Unit: To be assigned  
For: Isolated Laminin 10 )

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents  
Washington, D.C. 20231

Dear Sir:

This prior art statement is filed under 37 C.F.R. §1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56.

In the judgment of the undersigned, the references listed on the attached Form PTO-1449 may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this statement or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102.

### Foreign Documents

1. WO 00/66730, issued November 9, 2000
2. WO 00/66731, issued November 9, 2000
3. WO 00/66732, issued November 9, 2000

### Other Documents

4. Altschul, et al., (1990), *J. Mol. Biol.*, 215:403-410.
5. Altschul, et al., (1997), *Nucleic Acids. Res.*, 25:3389-3402.
6. Aumailley and Kreig, (1996), *J. Invest. Dermatology*, 106:209-214.
7. Aumailley, et al., (1996), In The Laminins, Timpl and Ekblom, eds., Harwood Academic Publishers, Amsterdam, 127-158.
8. Aumailley, M., and Smyth, N., (1998), *J. Anat.*, 193(Pt 1):1-21.
9. Champliaud, MF, et al., (2000), *Experiment Cell Research*, 259(2): 326-35.
10. Church, HJ, et al., (1998), *Biochemical Journal*, 332(2): 491-8.
11. Clark, E. A. et al., (1995), *Science*, 268(5208): 233-9.
12. Cleland, et al., (1993), *Crit. Rev. Therapeutic Drug Carrier Systems*, 10:307-377.
13. Colognato, J., (1999), *J. Cell Biol.*, 145:619-631.
14. Davis, G. E., et al., (1995), *Exp. Cell Res.*, 216(1): 113-23.
15. De Arcangelis, A., et al., (2001), *International Journal of Cancer*, 94(1): 44-53.
16. Dejana, E., et al., (1993), *Kidney Int.*, 43(1): 61-5.
17. Dixit, P., et al., (2001), *J. Biomed. Mater. Res.*, 56(4): 545-55.
18. Durkin, ME, (1997), *FEBS Letters*, 411(2-3): 296-300.
19. Durkin, ME, (2001), "Homo sapiens laminin, alpha 5 (LAMA5), mRNA, " Accession No. NM005560
20. Eble, JA, (1998), *Biochemistry*, 37(31): 10945-55.
21. Ekblom, M., Falk, M., (1998), *Annals of the New York Academy of Sciences*, 857:194-211.
22. El Nemer, W., et al., (2001), *Journal of Biological Chemistry*, 276(26): 23757-62.

23. Engel, J., (1994), *Methods Enzymol.*, 245:469-88.
24. Faury, Ristori, G., et al., (1995), *Journal of Vascular Research*, 32(2): 112-9.
25. Ferletta, M. et al., (1999), *J. Cell Sci.*, 112(Pt. 1): 1-10.
26. Frojdman, K., et al., (1999), *Differentiation*, 64(3): 151-9.
27. Fujiwara, H., et al., (2001), *J. Biol. Chem.*, 276(20): 17550-8.
28. Geberhiwot, T., et al., (2001), *Journal of Cell Science*, 114(Pt. 2): 423-33.
29. Goodwin, AE, et al., (1995), *Journal of Immunological Methods*, 187(2): 213-9.
30. Gu, J., (2001), *Journal of Biological Chemistry*, 276(29): 27090-7.
31. Gu, Y., et al., (1999), *Blood*, 93(8): 2533-42.
32. Haegerstrand, A., et al., (1992), *J. Vasc. Surg.*, 16(2): 280-5.
33. Hellivwell, TR, et al., (1998), *Neuromuscular Disorders*, 8(3-4): 152-61.
34. Hunter, D.D., et al., (1989), *Cell*, 59(5): 905-13.
35. Iivanainen, A., et al., (1997), *J. Biol. Chem.*, 272(44): 27862-8.
36. Jansson, K., et al., (1998), *Eur. J. Vasc. Endovasc. Surg.*, 16(4): 334-41.
37. John, St., PL, et al., (2001), *Kidney International*, 60(3): 1037-46.
38. Kamiguchi, et al., (1998), *Ann. Rev. Neurosci.*, 21:97-125.
39. Kanda, S., et al., (1999), *Exp. Cell Res.*, 248(1): 203-13.
40. Karlin and Altschul, (1990), *Proc. Natl. Acad. Sci. USA*, 87:2264-2268.
41. Karlin and Altschul, (1993), *Proc. Natl. Acad. Sci USA*, 90:5873-5877.
42. Kikkawa, Y., et al., (1998), *J. Biol. Chem.*, 273(25): 15854-9.
43. Kikkawa, Y., et al., (2000), *J. Cell Sci.*, 113(Pt. 5): 869-76.
44. Kohler and Milstein, (1975), *Nature*, 256:495-497.
45. Kortesmaa, J. et al., (2000), *J. Biol. Chem.*, 275(20): 14853-9.
46. Kozak, M., (1991), *J. Cell Biol.*, 115(4): 997-903.
47. Lallier, T., et al., (1991), *Development*, 113(4): 1069-84.

48. Lange, TS, et al., (1994), *Experimental Cell Research*, 214(1): 381-8.
49. Ling, A. Dai, et al., (1999), *Hypertension*, 34(5): 1141-6.
50. Lin, L., et al., (2000), *Experimental Eye Research*, 70(4): 537-46.
51. Ljubimov AV, et al., (1998), *Journal of Histochemistry & Cytochemistry*, 46(9): 1033-41.
52. Madri, J.A., et al., (1988), *Am. J. Pathol.*, 132(1):18-27.
53. Madri, J.A., et al., (1991), *J. Cell Biochem.*, 45(2):123-30.
54. Malinda and Kleinman, (1996), *Cell Biol.*, *Int. J. Biochem*, 28:957-959.
55. Miner, J.H., et al., (1995), *J. Biol. Chem.*, 270(48): 28523-6.
56. Miner, J.H., et al., (1997), *J. Cell Biol.*, 137(3): 685-701.
57. Miner, J.H., et al., (1997) "Mus musculus laminin alpha 5 chain (Lama5) mRNA, partial cds." Accession No. U37501.
58. Miner, J.H., et al., (1998), *J. Cell Biol.*, 143(6): 1713-23.
59. Miner, J.H., et al., (2000), *Dev. Biol.*, 217(2): 278-89.
60. Nielsen, P.K., et al., (2000), *Journal of Biological Chemistry*, 275(19): 14517-23.
61. Nielsen, P.K., et al., (2001), *J. Biol. Chem.*, 276(14): 10906-12.
62. Parsons, SF, et al., (2001), *Blood*, 97(1): 312-20.
63. Patton, B. L., et al., (1997), *J. Cell Biol.*, 139(6): 1507-21.
64. Pedraza, C. Geberhiwot, (2000), *Journal of Immunology*, 165(10): 5831-8.
65. Pevec, W. C., et al., (1992), *J. Vasc. Surg.*, 16(1): 60-5.
66. Pierschbacher, M.D., et al., (1984), *Nature*, 309(5963): 30-3.
67. Pikkarainen, T., et al., (1992), *Eur. J. Biochem.*, 209(2):571-82.
68. Pinckard, et al., (1967), *Clin. Exp. Immunol.*, 2:331-340.
69. Pouliot, N., et al., (2000), *Experimental Cell Research*, 261(2): 360-71.
70. Pouliot, N., et al., (2001), *Exp. Cell Res.*, 266(1), 1-10.
71. Robbins, et al., (1987), *Diabetes*, 36:838-845.
72. Sanes, JR., et al., (1998), *Journal of Physiology*, 92(3-4): 167-72.

73. Seebacher, T., et al., (1997), *Experimental Cell Research*, 237(1): 70-6.
74. Shah, BH, et al., (1992), *Brain Research*, 589(2): 268-74.
75. Shattil, S.J., et al., (1997), *J. Clin. Invest.* 100(11 Suppl), S91-5.
76. Siler, U., Seiffert M., (2000), *Blood*, 96(13): 4194-203.
77. Sixt, M., (2001), *Journal of Cell Biology*, 153(5): 933-46.
78. Sixt, M., et al., (2001), *J. Biol. Chem.*, 276(22), 18878-87.
79. Skelton, HG, (1998), *American Journal of Dermatopathology*, 20(6): 547-50.
80. Sorokin, L. M., et al., (1997), *Dev. Biol.*, 189(2): 285-300.
81. Sorokin, L. M., et al., (1997), *Dev. Dyn.*, 210(4):446-62.
82. Sorokin, L., et al., (1994), *Eur. J. Biochem.*, 223(2):603-10.
83. Spessotto, P. Yin, et al., (2001), *Cancer Research*, 61(1): 339-47.
84. Tani, T., et al., (1999), *Exp. Cell Res.*, 248(1): 115-21.
85. Timpl, R., and Brown, J.C., (1994), *Matrix Biol.*, 14(4): 275-281.
86. Tokida, Y., et al., (1990), *J. Biol. Chem.*, 265(30): 18123-9.
87. Vanderboom, RJ, et al., (1989), *Journal of Reproduction & Fertility*, 87(1): 81-7.
88. Varani, J., et al., (1995), *Journal of Biomedical Materials Research*, 29(8): 993-7.
89. Virtanen, I., et al., (1997), *Am. J. Pathol.*, 150(4):1421-31.
90. Wang, YG, Samarel, et al., (2000), *Journal of Physiology*, 526(Pt. 1): 57-68.
91. Watelet, J., et al., (1997), *Ann. Vasc. Surg.*, 11(5): 510-9.
92. Wayner, E.A., et al., (1993), *J. Cell Biol.*, 121(5): 1141-52.
93. Wewer and Engvall, (1996), *Neuromusc. Disord.*, 6:409-418.
94. Woerly, S., et al., (1996), *Neuroscience Letters*, 205(3) 197-201.
95. Yurchenco, et al., (1997), *Proc. Natl. Acad. Sci.*, 94:10189-10194.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Date: April 24, 2002

By:

Respectfully Submitted,



David Harper  
Reg. No. 42,636  
**McDonnell, Boehnen Hulbert & Berghoff**  
300 South Wacker Drive  
Chicago, IL 60606

FORM PTO-1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 99-274-F	Serial No. 10/037,182
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> Karl Tryggvason, et al.		
		<b>Filing Date:</b> December 21, 2001	<b>Group:</b> TBA	

### U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Dat if Appropriat

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
	1.	WO 00/66730	Nov. 9, 2000				
	2.	WO 00/66731	Nov. 9, 2000				
	3.	WO 00/66732	Nov. 9, 2000				

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

4.	Altschul, et al., (1990), <i>J. Mol. Biol.</i> , 215:403-410.
5.	Altschul, et al., (1997), <i>Nucleic Acids. Res.</i> , 25:3389-3402.
6.	Aumailley and Kreig, (1996), <i>J. Invest. Dermatology</i> , 106:209-214.
7.	Aumailley, et al., (1996), In The Laminins, Timpl and Ekblom, eds. Harwood Academic Publishers, Amsterdam, 127-158.
8.	Aumailley, M., and Smyth, N., (1998), <i>J. Anat.</i> , 193(Pt 1): 1-21.
9.	Champliaud, MF, et al., (2000), <i>Experiment Cell Research</i> , 259(2): 326-35.
10.	Church, HJ, et al., (1998), <i>Biochemical Journal</i> , 332(2): 491-8.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

**FORM PTO-1449**  
(Rev. 2-32)

**U.S. Department of Commerce  
Patent and Trademark Office**

**Atty. Docket No.**

99-274-F

**Serial No.**

10/037,182

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



**Applicant:**

Karl Tryggvason, et al.

**Filing Date:**

December 21, 2001

**Group:**

TBA

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.).**

.	11.	Clark, E. A. et al., (1995), <i>Science</i> , 268(5208): 233-9.
.	12.	Cleland, et al., (1993), <i>Crit. Rev. Therapeutic Drug Carrier Systems</i> , 10:307-377.
.	13.	Colognato, J., (1999), <i>J. Cell Biol.</i> , 145:619-631.
.	14.	Davis, G. E., et al., (1995), <i>Exp. Cell Res.</i> , 216(1): 113-23.
.	15.	De Arcangelis, A., et al., (2001), <i>International Journal of Cancer</i> , 94(1): 44-53.
.	16.	Dejana, E., et al., (1993), <i>Kidney Int.</i> , 43(1): 61-5.
.	17.	Dixit, P., et al., (2001), <i>J. Biomed. Mater. Res.</i> , 56(4): 545-55.
.	18.	Durkin, ME, (1997), <i>FEBS Letters</i> , 411(2-3): 296-300.
.	19.	Durkin, ME, "Homo sapiens laminin, alpha 5 (LAMA5), mRNA, "Accession No. NM005560, May 30, 2001
.	20.	Eble, JA, (1998), <i>Biochemistry</i> , 37(31): 10945-55.
.	21.	Ekblom, M., Falk, M., (1998), <i>Annals of the New York Academy of Sciences</i> , 857:194-211.
.	22.	El Nemer, W., et al., (2001), <i>Journal of Biological Chemistry</i> , 276(26): 23757-62.
.	23.	Engel, J., (1994), <i>Methods Enzymol.</i> , 245:469-88.
.	24.	Faury, Ristori, G., et al., (1995), <i>Journal of Vascular Research</i> , 32(2): 112-9.
.	25.	Ferletta, M. et al., (1999), <i>J. Cell Sci.</i> , 112(Pt. 1): 1-10.
.	26.	Frojdman, K., et al., (1999), <i>Differentiation</i> , 64(3): 151-9.
.	27.	Fujiwara, H., et al., (2001), <i>J. Biol. Chem.</i> , 276(20): 17550-8.
.	28.	Geberhiwot, T., et al., (2001), <i>Journal of Cell Science</i> , 114(Pt. 2): 423-33.
.	29.	Goodwin, AE, et al., (1995), <i>Journal of Immunological Methods</i> , 187(2): 213-9.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

**FORM PTO-1449**  
(Rev. 2-32)

**U.S. Department of Commerce  
Patent and Trademark Office**

**Atty. Docket No.**

**Serial No.**

99-274-F

10/037,182

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



**Applicant:**

Karl Tryggvason, et al.

**Filing Date:**

December 21, 2001

**Group:**

TBA

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

.	30.	Gu, J., (2001), <i>Journal of Biological Chemistry</i> , 276(29): 27090-7.
.	31.	Gu, Y., et al., (1999), <i>Blood</i> , 93(8):2533-42.
.	32.	Haegerstrand, A., et al., (1992), <i>J. Vasc. Surg.</i> , 16(2): 280-5.
.	33.	Hellivwell, TR, et al., (1998), <i>Neuromuscular Disorders</i> , 8(3-4): 152-61.
.	34.	Hunter, D.D., et al., (1989), <i>Cell</i> , 59(5): 905-13.
.	35.	Iivanainen, A., et al., (1997), <i>J. Biol. Chem.</i> , 272(44): 27862-8.
.	36.	Jansson, K., et al., (1998), <i>Eur. J. Vasc. Endovasc. Surg.</i> , 16(4): 334-41.
.	37.	John, St., PL, et al., (2001), <i>Kidney International</i> , 60(3): 1037-46.
.	38.	Kamiguchi, et al., (1998), <i>Ann. Rev. Neurosci.</i> , 21:97-125.
.	39.	Kanda, S., et al., (1999), <i>Exp. Cell Res.</i> , 248(1): 203-13.
.	40.	Karlin and Altschul, (1990), <i>Proc. Natl. Acad. Sci. USA</i> , 87:2264-2268.
.	41.	Karlin and Altschul, (1993), <i>Proc. Natl. Acad. Sci USA</i> , 90:5873-5877.
.	42.	Kikkawa, Y., et al., (1998), <i>J. Biol. Chem.</i> , 273(25): 15854-9.
.	43.	Kikkawa, Y., et al., (2000), <i>J. Cell Sci.</i> , 113(Pt. 5): 869-76.
.	44.	Kohler and Milstein, (1975), <i>Nature</i> , 256:495-497.
.	45.	Kortesmaa, J. et al., (2000), <i>J. Biol. Chem.</i> , 275(20): 14853-9.
.	46.	Kozak, M., (1991), <i>J. Cell Biol.</i> , 115(4): 997-903.
.	47.	Lallier, T., et al., (1991), <i>Development</i> , 113(4): 1069-84.
.	48.	Lange, TS, et al., (1994), <i>Experimental Cell Research</i> , 214(1): 381-8.

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

**FORM PTO-1449**  
(Rev. 2-32)

**U.S. Department of Commerce  
Patent and Trademark Office**

**Atty. Docket No.**


99-274-F

**Serial No.**

10/037,182

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



**Applicant:**

Karl Tryggvason, et al.

**Filing Date:**

December 21, 2001

**Group:**

TBA

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.).**

49.	Ling, A. Dai, et al., (1999), <i>Hypertension</i> , 34(5): 1141-6.
50.	Lin, L., et al., (2000), <i>Experimental Eye Research</i> , 70(4): 537-46.
51.	Ljubimov AV, et al., (1998), <i>Journal of Histochemistry &amp; Cytochemistry</i> , 46(9): 1033-41.
52.	Madri, J.A., et al., (1988), <i>Am. J. Pathol.</i> , 132(1):18-27.
53.	Madri, J.A., et al., (1991), <i>J. Cell Biochem.</i> , 45(2):123-30.
54.	Malinda and Kleinman, (1996), <i>Cell Biol.</i> , <i>Int. J. Biochem</i> , 28:957-959.
55.	Miner, J.H., et al., (1995), <i>J. Biol. Chem.</i> , 270(48): 28523-6.
56.	Miner, J.H., et al., (1997), <i>J. Cell Biol.</i> , 137(3): 685-701.
57.	Miner, J.H. et al., "Mus Musculus laminin alpha 5 chain (Lama5) mRNA, partial cds.", Acession No. U37501, November 10, 1997.
58.	Miner, J.H., et al., (1998), <i>J. Cell Biol.</i> , 143(6): 1713-23.
59.	Miner, J.H., et al., (2000), <i>Dev. Biol.</i> , 217(2): 278-89.
60.	Nielsen, P.K., et al., (2000), <i>Journal of Biological Chemistry</i> , 275(19): 14517-23.
61.	Nielsen, P.K., et al., (2001), <i>J. Biol. Chem.</i> , 276(14): 10906-12.
62.	Parsons, SF, et al., (2001), <i>Blood</i> , 97(1): 312-20.
63.	Patton, B. L., et al., (1997), <i>J. Cell Biol.</i> , 139(6): 1507-21.
64.	Pedraza, C. Geberhiwot, (2000), <i>Journal of Immunology</i> , 165(10): 5831-8.
65.	Pevec, W. C., et al., (1992), <i>J. Vasc. Surg.</i> , 16(1): 60-5.
66.	Pierschbacher, M.D., et al., (1984), <i>Nature</i> , 309(5963): 30-3.
67.	Pikkarainen, T., et al., (1992), <i>Eur. J. Biochem.</i> , 209(2):571-82.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

**FORM PTO-1449**  
(Rev. 2-32)

**U.S. Department of Commerce  
Patent and Trademark Office**

**Atty. Docket No.**


**Serial No.**

99-274-F

10/037,182

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



**Applicant:**

Karl Tryggvason, et al.

**Filing Date:**

December 21, 2001

**Group:**

TBA

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

68.	Pinckard, et al., (1967), <i>Clin. Exp. Immunol.</i> , 2:331-340.
69.	Pouliot, N., et al., (2000), <i>Experimental Cell Research</i> , 261(2): 360-71.
70.	Pouliot, N., et al., (2001), <i>Exp. Cell Res.</i> , 266(1), 1-10.
71.	Robbins, et al., (1987), <i>Diabetes</i> , 36:838-845.
72.	Sanes, JR., et al., (1998), <i>Journal of Physiology</i> , 92(3-4): 167-72.
73.	Seebacher, T., et al., (1997), <i>Experimental Cell Research</i> , 237(1): 70-6.
74.	Shah, BH, et al., (1992), <i>Brain Research</i> , 589(2): 268-74.
75.	Shattil, S.J., et al., (1997), <i>J. Clin. Invest.</i> , 100(11 Suppl), S91-5.
76.	Siler, U., Seiffert M., (2000), <i>Blood</i> , 96(13): 4194-203.
77.	Sixt, M., (2001), <i>Journal of Cell Biology</i> , 153(5): 933-46.
78.	Sixt, M., et al., (2001), <i>J. Biol. Chem.</i> , 276(22), 18878-87.
79.	Skelton, HG, (1998), <i>American Journal of Dermatopathology</i> , 20(6): 547-50.
80.	Sorokin, L. M., et al., (1997), <i>Dev. Biol.</i> , 189(2): 285-300.
81.	Sorokin, L. M., et al., (1997), <i>Dev. Dyn.</i> , 210(4):446-62.
82.	Sorokin, L., et al., (1994), <i>Eur. J. Biochem.</i> , 223(2):603-10.
83.	Spessotto, P. Yin, et al., (2001), <i>Cancer Research</i> , 61(1): 339-47.
84.	Tani, T., et al., (1999), <i>Exp. Cell Res.</i> , 248(1): 115-21.
85.	Timpl, R., and Brown, J.C., (1994), <i>Matrix Biol.</i> , 14(4): 275-281.
86.	Tokida, Y., et al., (1990), <i>J. Biol. Chem.</i> , 265(30): 18123-9.

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Atty. Docket No.

99-274-F

Serial No.

10/037,182

Applicant:

Karl Tryggvason, et al.

Filing Date:

December 21, 2001

Group:

TBA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.).

•	87.	Vanderboom, RJ, et al., (1989), <i>Journal of Reproduction &amp; Fertility</i> , 87(1): 81-7.
	88.	Varani, J., et al., (1995), <i>Journal of Biomedical Materials Research</i> , 29(8): 993-7.
	89.	Virtanen, I., et al., (1997), <i>Am. J. Pathol.</i> , 150(4):1421-31.
	90.	Wang, YG, Samarel, et al., (2000), <i>Journal of Physiology</i> , 526(Pt. 1): 57-68.
	91.	Watelet, J., et al., (1997), <i>Ann. Vasc. Surg.</i> , 11(5): 510-9.
	92.	Wayner, E.A., et al., (1993), <i>J. Cell Biol.</i> , 121(5): 1141-52.
	93.	Wewer and Engvall, (1996), <i>Neuromusc. Disord.</i> , 6:409-418.
	94.	Woerly, S., et al., (1996), <i>Neuroscience Letters</i> , 205(3) 197-201.
	95.	Yurchenco, et al., (1997), <i>Proc. Natl. Acad. Sci.</i> , 94:10189-10194.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.